Flagship Pioneering’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Flagship Pioneering’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-797,720	Closed	-$18M	–	10
2023 Q2	$18M	Sell	797,720 -1	-0%	-$7	0.8%	7
2023 Q1	$9.65M	Hold	797,721	–	–	0.37%	8
2022 Q4	$3.63M	Hold	797,721	–	–	0.12%	10
2022 Q3	$5.18M	Hold	797,721	–	–	0.22%	11
2022 Q2	$8.61M	Hold	797,721	–	–	0.32%	10
2022 Q1	$15.2M	Hold	797,721	–	–	0.36%	12
2021 Q4	$28.6M	Hold	797,721	–	–	0.44%	11
2021 Q3	$58.6M	Hold	797,721	–	–	0.61%	10
2021 Q2	$111M	Hold	797,721	–	–	1.42%	9
2021 Q1	$232M	Hold	797,721	–	–	3.71%	6
2020 Q4	$498M	Buy	+797,721	New	+$362M	9.07%	2

Other funds holding SGTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Flagship Pioneering's SGTX Position: Q3 2023 in Review

Flagship Pioneering sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q3 2023, closing a stake of 797,720 shares — an estimated $18M sold.

Flagship Pioneering first reported a position in SGTX in Q4 2020 and held it in 11 quarters. The position peaked at $498M in Q4 2020. 1 fund tracked by Wall St. Rank holds SGTX as of Q3 2023.

Flagship Pioneering reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Flagship Pioneering sold 797,720 Sigilon Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $18M.
Flagship Pioneering first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2020 and held it in 11 quarters.
Flagship Pioneering's Sigilon Therapeutics, Inc. Common Stock position peaked at $498M in Q4 2020.
1 fund tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Flagship Pioneering's 13F filing for Q3 2023, filed 14 Nov 2023.